PMID- 21694835
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20110714
LR  - 20231104
IS  - 1178-7023 (Print)
IS  - 1178-7023 (Electronic)
IS  - 1178-7023 (Linking)
VI  - 2
DP  - 2009
TI  - Delayed release dexlansoprazole in the treatment of GERD and erosive esophagitis.
PG  - 117-28
AB  - Although proton pump inhibitors (PPI) have a record of remarkable effectiveness 
      and safety in the management of gastroesophageal reflux disease (GERD), several 
      treatment challenges with PPI have emerged. Dexlansoprazole MR is the 
      (R)-enantiomer of lansoprazole contained in a formulation that produces two 
      distinct releases of drug and significantly extends the duration of active plasma 
      concentrations and % time pH > 4 beyond that of conventional single-release PPI. 
      Dexlansoprazole MR can be administered without regard to meals or the timing of 
      meals in most patients. Dexlansoprazole MR 60 mg demonstrated similar efficacy 
      for healing of erosive esophagitis at 8 weeks compared with lansoprazole 30 mg, 
      and dexlansoprazole MR 30 mg was superior to placebo for maintenance of healed 
      erosive esophagitis at 6 months with 99% of nights and 96% of days heartburn-free 
      over 6 months in patients taking dexlansoprazole MR 30 mg. Superior relief of 
      heartburn occurred in patients taking dexlansoprazole MR 30 mg (55% 
      heartburn-free 24-hour periods) vs placebo (14%) for symptomatic nonerosive GERD. 
      The safety profile of dexlansoprazole MR is similar to that of lansoprazole. The 
      extended pharmacodynamic effects, added convenience, and efficacy and safety of 
      dexlansoprazole MR offer a novel approach to gastric pH control in patients with 
      acid-related disorders.
FAU - Wittbrodt, Eric T
AU  - Wittbrodt ET
AD  - Takeda Pharmaceuticals North America, Inc.
FAU - Baum, Charles
AU  - Baum C
FAU - Peura, David A
AU  - Peura DA
LA  - eng
PT  - Journal Article
DEP - 20091117
PL  - New Zealand
TA  - Clin Exp Gastroenterol
JT  - Clinical and experimental gastroenterology
JID - 101532800
PMC - PMC3108635
OTO - NOTNLM
OT  - GERD
OT  - TAK-390MR
OT  - dexlansoprazole MR
OT  - erosive esophagitis
OT  - gastroesophageal reflux disease
EDAT- 2009/01/01 00:00
MHDA- 2009/01/01 00:01
PMCR- 2009/11/17
CRDT- 2011/06/23 06:00
PHST- 2009/11/16 00:00 [received]
PHST- 2011/06/23 06:00 [entrez]
PHST- 2009/01/01 00:00 [pubmed]
PHST- 2009/01/01 00:01 [medline]
PHST- 2009/11/17 00:00 [pmc-release]
AID - ceg-2-117 [pii]
AID - 10.2147/ceg.s5765 [doi]
PST - ppublish
SO  - Clin Exp Gastroenterol. 2009;2:117-28. doi: 10.2147/ceg.s5765. Epub 2009 Nov 17.